Method of enhancing and/or inducing neuronal migration using erythropoietin

• US 20070111932A1
• Filed: 07/31/2003
• Published: 05/17/2007
• Est. Priority Date: 07/31/2003
• Status: Abandoned Application

• Current Assignee: Stem Cell Therapeutics Inc. (Pfizer Inc.)
• Original Assignee: Stem Cell Therapeutics Inc. (Pfizer Inc.)
• Inventors: Andersen, Linda
• Application Number:
  US10/558,661
• Publication Number:
  US 20070111932A1
• Time in Patent Office: Days
• US Class Current: 435/325
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 38/2257 Prolactin

Abstract

Methods are described for the enhancement and/or induction of migration of neural stem cells or neuronal progenitor cells. Multipotent neural stem cells are exposed to erythropoietin which enhances the migration of multipotent neural stem cells and neuronal progenitor cells. The erythropoietin may be exogenously applied to the multipotent neural stem cells, or alternatively, the cells can be subjected to hypoxic insult which induces the cells to express erythropoietin. In a preferred embodiment, additional growth factors, such as EGF and prolactin, are utilized.

Claims

1. A method of enhancing multipotent neural stem cell and/or multipotent neural stem cell progeny migration in a subject comprising administering an erythropoietin and at least one other growth factor to a subject in an amount effective to enhance migration of multipotent neural stem cells and/or multipotent neural stem cell progeny.

2. The method of claim 1, wherein the at least one other growth factor is epidermal growth factor (EGF).

3. The method of claim 2, wherein the EGF is EGF51N or EGF51Q.

4. The method of claim 1, wherein the at least one other growth factor is prolactin.

5. The method of claim 1, wherein the erythropoietin is administered concurrently with the at least one other growth factor.

6. The method of claim 1, wherein the erythropoietin is administered sequentially with the at least one other growth factor.

7. The method of claim 1, wherein the at least one other growth factor is administered prior to the erythropoietin.

8. The method of claim 1, wherein the at least one other growth factor is administered after the erythropoietin.

9. The method of claim 1, wherein said subject is suffering from a neurodegenerative disease or brain injury.

10. The method of claim 9, wherein the subject is suffering from stroke.

11. The method of claim 1, wherein the multipotent neural stem cells and/or multipotent neural stem cell progeny migrate to the basal ganglia.

12. The method of claim 1, wherein the multipotent neural stem cells and/or multipotent neural stem cell progeny migrate towards a lesioned or damaged area of the brain of the subject.

13. The method of claim 1, wherein said subject is a human.

14. The method of claim 1, wherein the multipotent neural stem cells and/or progenitor cells which are derived from said multipotent neural stem cells are transplanted into said subject.

15. The method of claim 14, wherein said multipotent neural stem cells and/or progenitor cells are incubated with the erythropoietin and at least one other growth factor before being transplanted into said subject.

16. A method of inducing the migration of multipotent neural stem cells and/or multipotent stem cell progeny comprising exogenously adding to said multipotent neural stem cells and/or multipotent neural stem cell progeny an amount of an erythropoietin and at least one other growth factor effective to cause the migration of multipotent neural stem cells and/or multipotent neural stem cell progeny.

17. The method of claim 16, wherein the at least one other growth factor is epidermal growth factor (EGF).

18. The method of claim 17, wherein the EGF is EGF51N or EGF51Q.

19. The method of claim 16, wherein the at least one other growth factor is prolactin.

20. The method of claim 16, wherein the erythropoietin is added concurrently with the at least one other growth factor.

21. The method of claim 16, wherein the erythropoietin is added sequentially with the at least one other growth factor.

22. The method of claim 16, wherein the at least one other growth factor is added prior to the addition of the erythropoietin.

23. The method of claim 16, wherein the at least one other growth factor is added after the addition of the erythropoietin.

24. A method for inducing migration of multipotent neural stem cells and/or multipotent neural stem cell progeny, comprising exposing said multipotent neural stem cells and/or multipotent neural stem cell progeny to hypoxic conditions to induce expression of erythropoietin and exogenously adding at least one other growth factor in an amount effective to induce migration.

25. The method of claim 24, wherein said at least one other growth factor is epidermal growth factor (EGF).

26. The method of claim 25, wherein the EGF is EGF51N, or EGF51Q.

27. The method of claim 24, wherein the at least one other growth factor is prolactin.

28. The method of claim 24, wherein said at least one other growth factor is added to said multipotent neural stem cells and/or multipotent neural stem cell progeny concurrently with hypoxic conditions.

29. The method of claim 24, wherein said at least one other growth factor is added to said multipotent neural stem cells and/or multipotent neural stem cell progeny sequentially with hypoxic conditions.

30. The method of claim 24, wherein said at least one other growth factor is added to said multipotent neural stem cells and/or multipotent neural stem cell progeny prior to exposure to hypoxic conditions.

31. The method of claim 24, wherein said at least one other growth factor is added to said multipotent neural stem cells and/or multipotent neural stem cell progeny after exposure to hypoxic conditions.